Miscellaneous Pulmonary Agents

• COPD Class Update - Dec 05, 2024
• Asthma and COPD maintenance medications - Oct 01, 2020
• Asthma Biologics - Jul 26, 2018

• Monoclonal Antibodies for Asthma - Jul 28, 2016
• Asthma and COPD - Sep 24, 2015
• COPD/Asthma Class Update - Jul 31, 2014
• COPD Class Update and Breo Ellipta New Drug Evaluation - Nov 21, 2013
• Class Scan: COPD Medications - Sep 26, 2013
• Drug Class Review: Controller Medications for Asthma - Jul 25, 2013
• Class Update: Asthma Controllers - May 31, 2012
• Abbreviated Class Review: COPD - Feb 23, 2012

• July 2025 - New Therapies for Treatment of Chronic Obstructive Pulmonary Disease
• December 2020 - 2019-2020 Food and Drug Administration Drug Safety Communications Update
• June 2013 - Updates and Future Perspectives in the Management of Stable Chronic Obstructive Pulmonary Disease

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.